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ABSTRACT

Despite the common usage of high-dose vitamin C among breast cancer patients,
the published medical literature is not in agreement as to how mega-dose vitamin C may
interact with conventional therapy to affect clinical outcomes. The purpose of this study
was to investigate the interaction of mega-dose vitamin C with radiation therapy and with
doxorubicin in the treatment of breast cancer. Cultures of EMT6 mouse mammary tumor
cells were treated concurrently with varying dose of vitamin C and either radiation or
doxorubicin. A clonogenic assay was then performed to determine the surviving fraction
of the cells. The surviving fractions of cells in cultures receiving different doses of
vitamin C were compared among themselves as well as with controls and dose response
curves were generated. Results show that ascorbic acid administered in concentrations of
1 mM or 10 mM 4 hours before x-irradiation protected the cells from radiation-induced
cytotoxicity.

The dose-modifying factors for 1 mM and 10 mM ascorbic acid as

compared to controls were 1.23 and 1.37 respectively.

These results support the

hypothesis that mega-dose vitamin C, when taken concurrently with radiation therapy,
protects cancer cells from the cytotoxic effects of ionizing radiation. No evidence was
found to suggest that mega-dose vitamin C alters the antineoplastic effects of doxorubicin.
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INTRODUCTION

Prevalence of Complementary and Alternative Medicine Use among Cancer
Patients

The

National

Center

for

Complementary

and

Alternative

Medicine

(http://nccam.nih.gov/), a component of the National Institutes of Health, defines
complementary and alternative medicine (CAM) as “a group of diverse medical and
health care systems, practices, and products that are not presently considered to be part of
conventional medicine.”

Complementary medicines are used concomitantly with

conventional medicine, whereas alternative medicines are used to substitute for
conventional medicine.

It is well documented that CAM is widely used by cancer patients. In 1998, Ernst
and Cassileth published a review of the literature documenting the prevalence of CAM
use among cancer patients. They reviewed 26 surveys from 13 countries which found a
prevalence of CAM use among adult cancer patients ranging from 7 to 64 percent with an
average prevalence of 31.4 percent (1). The study authors attribute this wide variability to
a lack of specificity in the definition of CAM within studies and inconsistency in its
definition between studies. Nevertheless, they conclude that the use of CAM by cancer
patients is both common and widespread. That same year, a national survey conducted
by Eisenberg et al. found that the prevalence of CAM use among the general population
increased from 33.8 percent in 1990 to 42.1 percent in 1997 (p ≤ 0.001) (2). According
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to the survey results, one of the therapies that increased the most during that time was
megavitamins, defined by Dictionary.com as “a dose of a vitamin greatly exceeding the
amount required to maintain health.”

Since 1998, multiple new studies have been published which further support the
high prevalence of CAM use among cancer patients.

In a study of CAM use by breast

cancer survivors in Ontario, Canada, 66.7 percent of the survey respondents reported
using CAM (3). In a cohort study of 480 patients in Massachusetts with newly diagnosed
early-stage breast cancer, 10.6 percent of the study participants had used CAM prior to
being diagnosed with breast cancer, and 28.1 percent initiated new use of CAM after
surgery for their cancer (4). A 2004 survey of 500 women with breast or gynecologic
cancers at the M.D. Anderson Cancer Center found that 48 percent of the women used
CAM (5). In a study of patients with advanced-stage breast cancer, 73 percent of patients
reported using CAM (6). Given the high prevalence of CAM use among cancer patients,
an understanding of the interactions of CAM with conventional cancer therapies is
clinically important.

Vitamin C

Vitamin C (ascorbic acid) is an important water-soluble dietary vitamin. It is
absorbed in the distal small intestine via a sodium-dependent cotransport mechanism ( 7 )
and excreted renally. The recommended daily allowance of vitamin C for females is
75 mg and for males is 90 mg; daily intake should not exceed 2000 mg (8). Nearly all of
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the vitamin C ingested is absorbed into the circulation up to a daily intake of 100 mg (9).
However, as ingestion increases above this dose, a progressively smaller percentage of
dietary vitamin C is absorbed (10). Scurvy is a clinical syndrome that develops with
vitamin C deficiency. Symptoms of scurvy include: petechiae, ecchymoses, bleeding
gums, hyperkeratosis, arthralgias, impaired wound healing, neuropathy, weakness,
malaise and depression (11). Symptoms of vitamin C overdose include renal calculi,
nausea, gastritis and diarrhea (8).

Although the mechanism of action of vitamin C is not yet fully understood, much
has been learned about the biochemical functions it performs, which are many and varied.
Vitamin C plays an important role in collagen synthesis and tissue repair ( 12 ). Many of
the symptoms observed in scurvy, for example, are due to impaired collagen synthesis
secondary to vitamin C deficiency. In the gut, vitamin C enhances iron absorption (13).
Once absorbed, vitamin C acts as a reversible reducing agent in a variety of biochemical
reactions involving iron and copper, in some cases resulting in the alteration of enzyme
activity ( 13 ). The antioxidant properties of vitamin C make it capable of stabilizing
molecular oxygen and scavenging free radicals (12).

Nobel laureate Linus Pauling’s 1979 book, Cancer and Vitamin C, opened the
public debate over the effectiveness of vitamin C in the prevention and treatment of
cancer. In this book, Pauling and his co-author, Ewan Cameron, argued that mega-dose
vitamin C improves clinical outcomes in cancer patients ( 14 ).

In support of their

argument, Cameron and Pauling presented the results of a study of 100 patients with

4
terminal cancer. These patients were given 10 g of vitamin C daily and their survival was
compared with that of 370 case controls. Results showed a remarkable increase in
survival time among the patients treated with high-dose vitamin C. The study was
criticized for exhibiting selection bias as the study cases were all Dr. Cameron’s patients
whereas case controls were taken from historical chart reviews of patients treated at a
different hospital.

A group at the Mayo Clinic subsequently attempted to confirm

Pauling’s findings by conducting a prospective, randomized, double-blind trial
comparing high-dose vitamin C with placebo in terminal cancer patients who had been
previously treated with conventional therapy (15). The Mayo Clinic group found instead
that the patients in the vitamin C arm of the study deteriorated more quickly than those in
the placebo arm. After receiving criticism from Dr. Pauling for including in their study
patients who had a prior history of chemotherapy (16), the Mayo Clinic group conducted
a second study with identical treatment arms but in patients who had not previously been
exposed to conventional cytotoxic chemotherapy (17, 18). Again, no benefit of vitamin
C was observed.

A significant amount of research has recently sought to answer the question of
whether vitamin C may have a role as an adjuvant therapy in the treatment of cancer
either to protect normal tissues or to potentiate antineoplastic activity. Current literature
will be reviewed separately for studies investigating the interaction of vitamin C with
radiation and with doxorubicin.
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Radiation

Radiation therapy is widely used in the treatment of human cancers and certain
other hyperproliferative diseases. Greater than 60 percent of cancer patients undergo
radiation therapy at some point during the course of their illness. Radiation therapy can
be used with curative intent, for palliation of symptoms or as adjuvant therapy (19).
Adjuvant radiation therapy may be used to shrink a tumor prior to surgery as well as to
kill remaining malignant cells following surgery.

Chemotherapy given prior to or

concomitantly with adjuvant radiotherapy may make tumors more sensitive to the effects
of radiation. Two of the most common methods of delivering radiation to patients are
external beam radiation, which uses a linear accelerator, cobalt-60 irradiator or other
machine to deliver radiation from outside the body to the tumor, and brachytherapy in
which γ-radiation is delivered directly to the tumor from within the body ( 20 ).
Brachytherapy implants can be intracavitary, interstitial or intravenous. Of course, the
goal in devising any radiation treatment plan is to kill cancer cells with the greatest
possible efficacy while minimizing damage to normal tissue.

When radiation is absorbed by living tissue, energy may be transferred to an
electron causing excitation of that electron. Radiation that has sufficient energy to eject
an orbital electron from the atom is referred to as ionizing radiation. There are several
different types of ionizing radiation that are used clinically in therapeutic radiology.
X-rays and γ-rays are both electromagnetic radiations with similar spectrums of
frequency and energy, which produce ionization (19, 20). When orbital electrons change
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between high-energy and low-energy states, x-rays are emitted that contain the energy
released in these transitions.

Gamma rays are emitted from the nuclei of certain

radioactive elements as they decay.

Particulate radiations (i.e. electrons, protons,

α-particles, neutrons or other particles accelerated to high velocities) can also produce
ionization (19, 20). Both electromagnetic and particulate radiations are used in cancer
therapy.

X-ray photons are typically absorbed by tissue in one of two ways: by Compton
scattering or by photoelectric absorption (20, 21). Pair production, a third way in which
a photon can be absorbed, results in the production of an electron-positron pair. This
occurs only when the photon energy is greater than 1.02 MeV, a condition that is not met
in the experiments conducted for this thesis. In Compton scattering, which dominates at
high energies, the incident photon transfers a portion of its energy to a loosely bound
electron of an atom of the absorbing tissue causing that electron to be ejected from the
atom as a fast-moving particle (see Figure 1). The photon, deflected from its original
path, continues with the remaining energy. In contrast, when radiation is absorbed by the
photoelectric process, which dominates at low energies, the incident photon interacts with
a tightly bound electron, transferring all of its energy to that electron (see Figure 2). The
resultant fast-moving electron, having been ejected from the atom, has a kinetic energy
equal to the energy of the incident photon minus the electron’s binding energy. The
vacancy left by the ejected electron is filled either by an outer orbital electron from
within the same atom or by an electron from outside the atom. This filling of the vacancy
causes the emission of characteristic x-rays. Regardless of whether x-rays are absorbed
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FIGURE 1. Absorption of an x-ray photon by Compton scattering. The incident
photon transfers a portion of its energy to a loosely bound electron of an atom of the
absorbing tissue causing that electron to be ejected from the atom as a fast-moving
particle. The photon, deflected from its original path, proceeds with reduced energy.
Key: e- represents an electron; p+ represents a proton; n represents a neutron. This
figure was adapted from Hall (20).
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FIGURE 2.

Absorption of an x-ray photon by the photoelectric process. The

incident photon interacts with a tightly bound electron, transferring all of its energy to
that electron and ejecting the electron from the atom. The vacancy left by the ejected
electron is filled either by an outer orbital electron from within the same atom or by an
electron from outside the atom. This filling of the vacancy causes the emission of
characteristic x-rays. Key: e- represents an electron; p+ represents a proton; n represents
a neutron. This figure was adapted from Hall (20).
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by Compton scattering or by the photoelectric process, the production of fast-moving free
electrons is essential to cause damage to critical molecules such as DNA.

Ionizing radiation can damage DNA either directly or indirectly (20). If an
incident photon happens to be absorbed by a critical molecule such as DNA, that photon
can cause direct biological damage. The vast majority of radiation-induced damage,
however, is produced indirectly.

In this case, free electrons produced by photon

absorption interact with nearby molecules, commonly with water, to produce free radicals
(22). Free radicals are highly reactive atoms or molecules that carry an unpaired orbital
electron in an outer shell. These free radicals initiate a chain of reactions with other
nearby molecules to produce a large number of ions, free radicals and other chemically
reactive species that then go on to damage critical cellular molecules, most importantly
DNA (22).

The damaging biologic effects of indirectly acting radiation can be modified by
chemical agents that act as either radiosensitizers or radioprotectors (20, 22, 23). This is
in contrast to the direct action of radiation that cannot be modified by these agents. A
radiosensitizer is a chemical agent that increases the damage induced by a given dose of
radiation, whereas a radioprotector prevents or diminishes the damage produced by the
radiation.

In other words, radiosensitizers cause decreased cell survival following

radiotherapy, steepening the slope of the radiation dose-response curve; while
radioprotectors cause increased cell survival, decreasing the slope of the curve (see the
Materials and Methods section for more information on dose-response curves).
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Molecular oxygen is an example of a radiosensitizer. Oxygen is a frequent participant in
chemical reactions that produce the ions and free radicals which go on to cause biologic
damage. On the other hand, chemical compounds that scavenge free radicals can protect
cells and tissues from the damaging effects of radiation. Antioxidants, because of their
properties as free radical scavengers, have been studied as potential clinically important
radioprotectors (23).

In order to study the effects of agents that might alter the cellular response to
radiation, it is important to have a precise definition of what we mean by “cell survival.”
When discussing the survival of cancer cells, the clinically relevant question to ask is
whether the cells have the capacity to grow and form a tumor, to locally invade
surrounding tissues, or to metastasize to distant sites. After being irradiated, a given
tumor cell might continue to live and carry on with its metabolic functions; but if it is
unable to divide indefinitely to produce a large number of daughter cells, it has become
clinically inconsequential and can be considered dead. Hall refers to this phenomenon as
“reproductive death” (20). In order to be considered a survivor, a cell must maintain the
capacity to produce a colony of new cells. In other words, cell survival is defined in
terms of clonogenicity.

Current in vitro data available from the scientific literature is inconclusive in
respect to the possible interaction between high-dose vitamin C and radiotherapy. In
vitro experiments conducted by Witenberg et al. demonstrated that preincubation with an
ascorbic acid derivative protects HL60 myeloid leukemia cells against x-irradiation-
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induced apoptosis (24). In a study of normal human lymphocytes treated with radiation
in vitro, Konopacka and Rzeszowska-Wolny found evidence for a radioprotective effect
of vitamin C at all tested concentrations when the vitamin was administered after
irradiation ( 25 ). When given prior to irradiation, vitamin C was found to have a
significant protective effect at low concentration (1 µg/mL) and a sensitizing effect at the
highest concentration tested (20 µg/mL), though the sensitizing effect was not significant.
Ortmann et al. studied the effect of vitamin C on radiation-induced apoptosis in normal
human lymphoblastic cells in vitro (26). When given prior to irradiation, vitamin C had
a slight but statistically significant radiosensitizing effect at 100 µM, the highest
concentration tested.

When given immediately after irradiation, vitamin C had a

radioprotective effect at 0.01 µM, the lowest concentration tested.

The cumulative data obtained from animal models have been similarly
inconclusive. In their study of Ehrlich ascites tumor cells in vivo, Koch and Biaglow
found that dehydroascorbate, a metabolite of vitamin C, sensitized the tumor cells to
radiation (27). Tewkif et al. administered ascorbic acid to mice in vivo and studied its
effects on solid tumor growth and on tumor control by radiation (28). They found that
tumor growth was significantly faster in control mice compared to mice receiving vitamin
C. Additionally, tumor control by radiation was better in the ascorbic acid group than in
controls. Okunieff performed in vivo experiments in mice investigating the effect of
high-dose ascorbic acid on the radiation response of both normal tissues and transplanted
tumor (29). Results showed that vitamin C protected normal bone marrow and skin from
radiation damage without affecting the dose of radiation required to control 50 percent of
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tumors or to achieve remission. Sarma and Kesavan found vitamin C to have a protective
effect against γ-ray-induced chromosomal damage in mice as evidenced by a reduction in
the frequency of micronuclei and chromosomal aberrations in the bone marrow cells of
vitamin C-treated mice compared to controls after whole body γ-irradiation ( 30 ).
Konopacka et al. conducted in vivo experiments in mice investigating the modifying
effect of vitamin C on the clastogenic activity of γ-rays as measured by the number of
micronuclei in bone marrow polychromatic erythrocytes and exfoliated bladder cells (31).
When given before irradiation, vitamin C was found to be a radioprotector at low doses
(50-100 mg/kg/day) and a radiosensitizer at the highest dose tested (400 mg/kg/day).
When given after irradiation at the same high dose, however, vitamin C acted as a
radioprotector.

Given the high prevalence of CAM use among cancer patients and the
inconclusive results of the experimental data to date, the question of whether high-dose
vitamin C alters the efficacy and/or toxicity of radiotherapy is an important clinical
question to answer so that clinicians may better advise their patients.

Doxorubicin

Doxorubicin is an intravenously administered chemotherapeutic agent used
commonly in the treatment of many cancers including cancers of the breast, endometrium
and thyroid as well as both acute lymphocytic and acute myelogenous leukemias,
Hodgkin’s and non-Hodgkin’s lymphomas, osteosarcoma, Kaposi’s sarcoma, and soft-
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tissue sarcomas.

Acute and reversible adverse effects of doxorubicin include

myelosuppression, nausea, vomiting and cardiac arrhythmias.

The most important

adverse effect of the drug, however, which may develop after weeks or months of
repeated treatments with doxorubicin is irreversible chronic cardiomyopathy.

The

development of cardiomyopathy secondary to doxorubicin is related to the total
cumulative dose of drug given (32). For this reason, it has been recommended that
patients receive a total cumulative dose no greater than 550 mg/m2 of body surface area
(32) and that cardiac performance be assessed prior to the initiation of, during, and after
completion of therapy with doxorubicin (33).

Doxorubicin is classified as an anthracycline antibiotic. Although its mechanism
of action is not fully understood, doxorubicin is believed to cause its antineoplastic
effects through a multifactorial, complex process. Multiple mechanisms of action have
been proposed. For example, it has been postulated that doxorubicin alters DNA in a
number of ways including: inducing DNA strand breaks, inducing DNA cross-links,
interfering with DNA strand separation and helicase activity, or inhibiting DNA synthesis
by intercalating with the sugar phosphate backbone or inhibiting DNA polymerase (34).
A second category of proposed mechanisms has to do with disruption of membranes.
Doxorubicin has been found to cause a dose-related decrease in membrane fluidity (35)
as well as altering other membrane properties (36). A third major class of hypothesized
mechanisms involves the generation of free radicals and other reactive oxygen species
(34).

This is one of the main mechanisms believed to be responsible for the

cardiotoxicity of the drug.
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In theory, free radical scavengers (such as antioxidants, which bind to free
radicals thereby preventing oxidative damage) could protect cardiac and other normal
tissues from the free radical-mediated damage caused by doxorubicin. The resultant
reduction in adverse effects could allow for the use of increased drug doses leading to a
possible improvement in tumor control. However, consideration must be given to the
possibility that any protection provided to normal tissues may also be afforded to the
tumor, essentially protecting cancer cells from the very treatment intended to destroy
them.

Cell culture and animal model data examining the interaction of vitamin C and
doxorubicin is inconclusive.

Wells et al. studied the effect of L-ascorbic acid

2-phosphate, a less active and more stable ascorbate derivative, on doxorubicin toxicity in
two strains of human breast cancer cells, one that is doxorubicin-sensitive and one that is
doxorubicin-resistant. Whereas L-ascorbic acid 2-phosphate had no effect on the survival
of cells of the doxorubicin-sensitive strain, it caused enhanced resistance in cells of the
doxorubicin-resistant strain (37). A separate study of human breast cancer cells treated
in vitro with doxorubicin found that vitamin C potentiated the cytotoxicity of doxorubicin
( 38 ). Shimpo and Fujita et al. studied the effects of ascorbic acid and two of its
derivatives, CV-3611 and ascorbyl palmitate, on both the antitumor activity and the
cardiotoxicity of doxorubicin in mice and guinea pigs (39, 40). They found that the
incidence of doxorubicin-induced cardiomyopathy was significantly decreased in the
animals receiving ascorbic acid while antitumor activity was not reduced. Furthermore,
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mice and guinea pigs treated with any of the three forms of vitamin C together with toxic
doses of doxorubicin lived longer than those treated with doxorubicin alone. Atunes and
Takahashi investigated the effect of vitamin C on normal bone marrow cells of the Wistar
rat treated with doxorubicin in vivo (41). They found that only the lowest studied dose of
vitamin C demonstrated a protective effect as measured by total number of chromosome
aberrations.

The highest doses of vitamin tested produced no change in outcome

compared to control.

Given the high prevalence of CAM use among cancer patients and the
contradictory nature of the data available to date, the question of whether high-dose
vitamin C alters the efficacy and/or toxicity of doxorubicin is an important clinical
question to answer so that clinicians may better advise their patients.

EMT6 In Vivo – In Vitro Tumor System

Given the technical and ethical limitations of studying tumor response to therapy
in humans, experimental oncology has been faced with the challenge of developing
animal and cell culture models for human cancers that lend themselves to
experimentation. Spontaneous tumors, while valuable experimental models, present a
high level of variability, offer only small numbers of homogeneous tumors for
experimentation, and are difficult to use in the measurement of therapeutic efficacy of
different treatments. Inbred rodent strains make available large numbers of genetically
identical animals, which have the benefit of greatly reducing variability in in vivo
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experiments. These animals can be used to study transplanted tumor lines or to induce
and study autochthonous tumors, tumors studied in the host of origin. In vitro models
allow for even greater control over the experimental environment and interventions as
well as more precise assays of cell survival. Despite having ideal characteristics for
experimental manipulation, however, cells studied in vitro are not a perfect model for
tumors existing in vivo. Unlike cells grown in culture, cells within a single tumor exist in
different states of proliferation and in a variety of different environments in terms of
oxygen concentrations, pH, nutrient availability and other parameters. In vivo-in vitro
cell lines have been developed to address this problem.

In vivo-in vitro cell lines are transplanted tumor cell lines that have been selected
or adapted for growth in cell culture. Prior to the development of an in vivo-in vitro tumor
system, data from cell culture was compared with that from animal experiments using
different cell lines. The great advantage of an in vivo-in vitro tumor system is that it
allows for study of a single cell line both in culture and in animals, thereby benefiting
from the advantages offered by both models. For example, cells can be injected into
research animals and the subsequent tumors studied and treated in an environment that
closely resembles that of spontaneous human tumors. These same solid tumor cells,
having been treated in vivo, can then be suspended, plated and assayed in vitro for cell
survival.

The EMT6 cell line, used in all experiments of the present study, is an in vivo-in
vitro tumor system first isolated and characterized by Rockwell et al. (42). The original
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tumor was the primary mammary tumor KHJJ-1 that arose in a BALB/c mouse. This
tumor was serially transplanted in BALB/c mice and then put into culture. After multiple
in vitro passages, the cell line was cloned and several of the clones characterized. The
sixth clone, EMT6, was selected for having desirable characteristics for a model system
to be used in experimental oncology. The EMT6 cell line grows rapidly in culture with a
doubling time of about 12 to 16 hours, has a high plating efficiency of about 80 percent,
and produces tumors when injected into BALB/c mice (43). Because of its lack of
differentiation, the EMT6 tumor cell line, like all in vivo-in vitro tumor systems, should
be considered a model for aggressive, rapidly growing tumors in general as opposed to
being a model for a narrower subset of human tumors which share the same histology as
the EMT6 cell line.
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STATEMENT OF PURPOSE

To investigate the potential clinical significance of the concomitant use of
mega-dose vitamin C with conventional cancer therapies, I asked whether ascorbic acid
alters the response of breast cancer cells in vitro either to radiation or to doxorubicin, a
commonly used antineoplastic agent. The interactions of varying doses of L-ascorbic
acid with ionizing radiation and doxorubicin were analyzed using cultures of EMT6
mouse mammary carcinoma cells, the specific aim being to elucidate any modifying
effect of the vitamin on the antineoplastic effects of treatment.
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MATERIALS AND METHODS

Cell Culture

EMT6 mouse mammary carcinoma cells (sub-line EMT6-Rw) were used for all
experiments. Experimental cell cultures were initiated using exponentially growing cells
from already established cell lines. These cells were incubated at 37ºC in a humidified
atmosphere of 95 percent air and 5 percent CO2. Stock cultures were routinely passed by
laboratory personnel using Waymouth’s medium supplemented with 15 percent serum
(made up of fetal clone and fetal bovine serum at a 1:1 ratio), and antibiotics (100 U/mL
penicillin-G, 100 µg/mL streptomycin sulfate, 5 µg/mL gentamycin and 0.125 µg/mL
fungizone). To ensure tight control of L-ascorbic acid levels, experimental cultures were
grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10 percent
dialyzed fetal bovine serum (dFBS), neither of which contain ascorbic acid or other
redox-active small molecules.

The experimental culture medium was additionally

supplemented with the same antibiotics as the Waymouth’s medium described above.
All cell cultures were grown in 60-mm Petri dishes.

Drugs and Radiation

Powdered L-ascorbic acid, obtained from Sigma-Aldrich, was stored at room
temperature and protected from light to prevent degradation. Immediately prior to each
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experiment, ascorbic acid powder was dissolved in sterile phosphate-buffered saline
(PBS) at a pH of 7.1 and sterilized by filtration through a 0.22-µm filter. The solution
was then protected from light until it was added to the cell culture medium. Petri dishes
were immediately returned to the incubator after addition of ascorbic acid to minimize
light exposure.

Cells were irradiated with graded doses of radiation using 250 kVp x-rays (15 mA,
2 mm A1 equivalent filtration) from a Siemen’s Stabilipan x-ray therapy machine at a
dose rate of 1.1 Gy/min.

Doxorubicin was obtained from American Pharmaceutical Partners, Inc.

Growth Experiments

Preliminary growth studies were performed to determine the toxicity of
L-ascorbic acid in the absence of radiation or antineoplastic agents.

EMT6 mouse

mammary tumor cells were harvested from exponentially growing cultures and plated
into 60-mm dishes in a total of 5 mL DMEM and at an initial concentration of 2 x 105
cells per dish. Prior to cell plating, the culture medium was allowed to equilibrate in the
incubator to attain the proper pH and temperature. Four hours after cell culture initiation,
the plated cells were treated with solutions of high purity L-ascorbic acid powder
dissolved in PBS to produce concentrations of 100 µM, 1 mM or 10 mM in the culture
medium. A fourth group, not treated with ascorbic acid, served as the control. Each of
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the four groups was then incubated and allowed to grow. Each day, two Petri dishes were
selected from each treatment group. The cells in these dishes were suspended and
counted; and the number of cells per dish was calculated. Cells from one dish per group
were plated and a colony formation assay was performed to assess viability (see below
for details). Although this experiment was repeated twice, the first experiment followed
the growth of the cells in cultures for only 2 days. When the experiment was repeated,
cell growth was studied daily for 4 days. The duration of the study was chosen so that
the cultures were followed throughout the period when the control cultures were expected
to be in exponential growth. Only data from the second experiment is shown.

Radiation Experiments

To determine the effect of L-ascorbic acid on cellular radiosensitivity,
exponentially growing stock EMT6 tumor cells were trypsinized, suspended in DMEM,
counted and diluted to a concentration of 2 x 105 cells/mL. One mL of cells was then
plated into each of 18 Petri dishes containing 4 mL of DMEM that had been previously
equilibrated to the proper pH and temperature. Cultures were incubated for 3 days under
the conditions described above, allowing the cells to reach the middle of the exponential
growth phase prior to treatment. After 3 days of growth, the medium was removed from
all dishes and replaced with fresh DMEM. Two treatment groups were then treated with
solutions of high purity L-ascorbic acid powder dissolved in PBS to produce
concentrations of either 1 mM or 10 mM in the culture medium. Cultures grown and
treated under identical conditions but in the absence of L-ascorbic acid were used as
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controls. After 4 hours of exposure to ascorbic acid, cells were irradiated with doses of
0.0, 2.5, 5.0, 7.5 or 10.0 Gray. Immediately following irradiation, the medium was
removed from the cultures, and the cells were washed, detached from the dish using
0.05 percent trypsin, suspended in Waymouth’s medium and assayed for colony
formation (see below for details). This experiment was repeated three times.

Doxorubicin Experiments

To determine the effect of L-ascorbic acid on clonogenic cell survival after
treatment with doxorubicin, exponentially growing stock EMT6 tumor cells were
trypsinized, suspended in DMEM, counted and diluted to a concentration of 2 x 105
cells/mL. One mL of cells was then plated into each of 15 Petri dishes containing 4 mL
of DMEM that had been previously equilibrated to the proper pH and temperature.
Cultures were incubated for 3 days allowing the cells to reach the middle of the
exponential growth phase prior to treatment. After 3 days of growth, the medium was
removed from all dishes and replaced with fresh DMEM. Two treatment groups were
then treated with solutions of high purity L-ascorbic acid powder dissolved in PBS to
produce concentrations of either 1 mM or 10 mM in the culture medium. Cultures grown
and treated under identical conditions but in the absence of L-ascorbic acid were used as
controls. After 2 hours of exposure to ascorbic acid, cells were treated with doxorubicin
at concentrations of 0.0, 0.1, 0.4, or 1.6 µg/mL. The doses of doxorubicin were selected
based on prior studies (44). After a total exposure time of 4 hours for ascorbic acid and
2 hours for doxorubicin, the medium was removed from the cultures, and the cells were
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washed, trypsinized, suspended in Waymouth’s medium and assayed for colony
formation as described below. This experiment was repeated three times.

Colony Formation Assay

To determine the survival of cells following treatment, colony formation assays
were performed for all experiments described above. After trypsinizatioin, the single-cell
suspensions were counted using a Coulter Counter model ZBI. Cell volume distributions
were also determined to ensure that the cell counts were accurate and uncompromised by
the clumping together of multiple cells. Cells were then diluted and plated at low
densities in Waymouth's medium. Each treatment group was plated at multiple different
densities to ensure that the resultant colonies would grow at such a density that individual
colonies could be distinguished and counted. Cells were then incubated and allowed to
grow for 2 weeks at which time the colonies were washed, fixed with methanol and
stained with crystal violet. Each culture was projected on the wall for magnification and
colonies of 50 cells or more were counted to determine the survival of cells with
clonogenic capacity. To ensure an objective count, colony counting was performed by
lab workers other than this student investigator who were blinded to the treatments
received by the cells in the different Petri dishes. All the cultures from each experiment
were counted by a single observer to prevent error from inter-observer variability.
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Data Analysis

After all the cultures from an experiment were counted, the plating efficiency of
each group was calculated. Plating efficiency (PE) is the percentage of single cells plated
that gives rise to colonies and is calculated by the following equation:

PE =

number of colonies formed
x100
number of cells plated

In these experiments the mean plating efficiency of untreated control cells was 94.0%
with a standard deviation of 15.1.

A surviving fraction (SF) for each treatment group was determined by taking the
ratio of the plating efficiency of the treated culture to that of the untreated control culture
(i.e. cells treated with neither ascorbic acid nor radiation) plated in the same experiment
on the same day:

SF =

treatment group plating efficiency
control group plating efficiency

These surviving fractions were used to generate a radiation dose-response curve. This
was accomplished by conducting a non-linear regression analysis using the StatMost
Statistical Package to obtain the best fit of the following equation to the experimental
data (20, 21):
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−D
⎛
⎞
SF = 1 − ⎜1 − e D0 ⎟
⎝
⎠

n

This equation defines the surviving fraction (SF) at a given radiation dose (D). The other
variables in the equation define different parts of the dose-response curve. D0 describes
the slope of the linear segment of the curve. Specifically, D0 is the dose required to
reduce the surviving fraction by 1 e on the linear portion of the curve. The extrapolation
number, n, is a description of the curve’s shoulder. More precisely, n is the calculated
surviving fraction at which the linear section of the survival curve, extrapolated back to
zero dose, hits the y-axis. Because vitamin C alone was found to produce a small toxic
effect in the radiation studies, the SF’s of the groups treated with vitamin C plus radiation
were normalized using the PE’s of the vitamin C-treated cultures before these curves
were fitted.

To quantify the extent to which vitamin C alters the radiation response of EMT6
cells, data from the dose-response curve was used to calculate the dose-modifying factor
(DMF) for ascorbic acid. DMF for radioprotectors is defined as the ratio of the dose of
radiation with the modifying agent (i.e. vitamin C) to the dose of radiation without the
agent that results in the same level of cell survival (20):

DMF =

radiation dose with modifying agent resulting in an SF of 0.1
radiation dose without modifying agent resulting in an SF of 0.1
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DMF’s were calculated by extrapolating the computer-fitted curves to a surviving
fraction of 0.1. A DMF greater than 1.0 indicates protection, whereas a DMF less than
1.0 indicates sensitization.

The Wilcoxon test was performed using the Statmost

Statistical Package to determine whether the differences between the curves were
statistically significant. Statistical significance was defined as a p-value of less than 0.05.
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RESULTS

Growth Experiments

Preliminary growth studies examined the growth curves for EMT6 cells to
determine the effects of different doses of ascorbic acid on the growth of these cells
in vitro. The three different concentrations of L-ascorbic acid used in the experiment
were 100 µM, 1 mM and 10 mM. Cells grown under identical conditions but in the
absence of ascorbic acid were used as controls. Figure 3 shows the growth curve of each
of the four groups of cells studied. No error bars are shown because this graph represents
data from one single experiment. When EMT6 cultures were grown in the presence of
1 mM or 10 mM concentrations of vitamin C, there was a significant reduction in cell
growth compared to control cultures. The cells grown in the presence of the smallest
concentration of vitamin C tested, 100 µM, showed a slight decrease in growth. This
slight reduction in cell growth, however, cannot be tested for statistical significance based
on data from only one experiment.

After counting the cells in each of the four groups to determine cell growth, the
cells were then assayed for clonogenic capacity. On each of the 4 days of the experiment,
cells from one dish per treatment group were plated in fresh media not containing any
ascorbic acid. The cells were incubated for 2 weeks and were then washed, fixed and
stained. Colonies of 50 cells or more were counted. In this way, the clonogenic capacity
was determined for cells after exposure to ascorbic acid for 1, 2, 3 or 4 days for each of
the 3 concentrations of vitamin C tested. Surviving fractions were then calculated by
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FIGURE 3.

Growth study of EMT6 cells grown in the presence of different

concentrations of L-ascorbic acid. Points are arithmetic means of cell numbers from 2
dishes, obtained in a single experiment. Key: λ represents control cells;  represents
cells treated with 100 µM L-ascorbic acid; ▼ represents cells treated with 1 mM
L-ascorbic acid; ∇ represents cells treated with 10 mM L-ascorbic acid.
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FIGURE 4.

Survival of EMT6 cells grown in the presence of different

concentrations of L-ascorbic acid. Each point is the surviving fraction of cells from
one dish, obtained in a single experiment. Key: λ represents control cells;  represents
cells treated with 100 µM L-ascorbic acid; ▼ represents cells treated with 1 mM
L-ascorbic acid; ∇ represents cells treated with 10 mM L-ascorbic acid.
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comparing the plating efficiencies of the treatment groups to that of the control group.
Figure 4 illustrates these surviving fractions. The cells exposed to 1 mM or 10 mM
vitamin C show a significant reduction in clonogenic capacity compared to cells in the
control group. This means that the presence of high concentrations of vitamin C in this
study not only caused a reduction in cell proliferation (see Figure 3), but also reduced the
capacity of existing cells to produce new colonies even after the vitamin was removed
from the culture medium (see Figure 4). Clonogenicity was seen to improve, however,
with increasing exposure time to the vitamin as illustrated by the positive slopes of the
lines graphed in Figure 4.

In summary, results of a preliminary growth study suggest a slightly toxic effect
of 100 µM vitamin C in comparison to control, and a significant toxicity of 1 mM and
10 mM L-ascorbic acid causing a reduction in both cell proliferation and clonogenic
capacity. The growth study results presented above were considered when choosing the
concentrations of ascorbic acid to be used in subsequent studies of the effect of vitamin C
on the outcomes of treatment with radiation and doxorubicin. Concentrations of 1 mM
and 10 mM L-ascorbic acid were selected for these subsequent experiments despite the
demonstrated toxicity of the vitamin at these levels. It is important to note that in the
preliminary growth study, cells were exposed to ascorbic acid for durations of 1, 2, 3 or 4
day, whereas the cells in subsequent experiments were exposed to the vitamin for only
4 hours.
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Radiation Experiments

Figure 5 shows data from experiments examining the effects of two different high
concentrations of L-ascorbic acid on the cellular radiosensitivity of EMT6 tumor cells.
Data points on the graph represent the geometric means ± the standard errors of the mean
(S.E.M.s) of surviving fractions determined in three independent experiments. Following
convention, radiation dose is plotted along the x-axis on a linear scale while surviving
fraction is plotted along the y-axis on a logarithmic scale. The curves representing cells
treated with 1 mM and 10 mM vitamin C have been corrected for ascorbic acid toxicity.
The surviving fractions for cells treated with vitamin C alone were 0.86 and 0.56 for cells
treated with 1 mM and 10 mM vitamin C, respectively. As expected, cell survival
decreases with increasing dose of ionizing radiation as illustrated by the down-sloping
curves in all three groups.

The figure shows a significant change in the radiosensitivity of cultures treated
with radiation plus vitamin C as compared to those treated with radiation alone. The
survival curve for cultures treated with 1 mM ascorbic acid lies above the control curve
on the graph. The difference between these two curves was found to be statistically
significant (p = 0.012). The survival curve for cultures treated with 10 mM ascorbic acid
lies even further above the control curve (p = 0.003) and well above the curve
representing survival of cells treated with the lower dose of vitamin C (p = 0.011). This
higher rate of cell survival among those cells exposed to high-dose ascorbic acid
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FIGURE 5. Effects of L-ascorbic acid on the radiation dose-response curve of
exponentially growing EMT6 cells. Points are geometric means ± standard errors of the
mean (S.E.M.s) of survivals determined in 3 independent experiments. Curves were
fitted as described in the Material and Methods section. Key: λ represents control cells;
 represents cells exposed to 1 mM L-ascorbic acid for 4 hours immediately prior to
irradiation; ▼ represents cells exposed to 10 mM L-ascorbic acid for 4 hours
immediately prior to irradiation.
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indicates a protective effect of the vitamin. Furthermore, this protective effect was
greatest at the highest concentration of vitamin C tested.

The dose-modifying factor (DMF), the ratio of the dose of radiation with the
modifying agent to the dose of radiation without the agent (in this case, vitamin C) that
results in the same level of cell survival (in this case, a surviving fraction of 0.10), was
calculated from these survival curves. A DMF greater than 1.0 indicates protection,
whereas a DMF less than 1.0 indicates sensitization. The DMF for 1 mM ascorbic acid
was calculated to be 1.23. This means that a concentration of 1 mM vitamin C alters the
antineoplastic effects of radiation such that in order to achieve the same level of cell
damage, a dose of radiation 23 percent higher would need to be given. The calculated
DMF for 10 mM ascorbic acid was 1.37, indicating that at this higher concentration of
vitamin C the radiation dose would need to be 37 percent higher in order to result in the
same level of radiation-induced damage.

In summary, the results of radiation

experiments show that mega-doses of vitamin C protect EMT6 mouse mammary tumor
cells from the cytotoxic effects of ionizing radiation.

Doxorubicin Experiments

Figure 6 shows data from experiments examining the effects of two different high
concentrations of L-ascorbic acid on the survival of EMT6 tumor cells treated with
doxorubicin. Data points on the graph represent the geometric means ± S.E.M.s of
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surviving fractions determined in three independent experiments. The surviving fractions
for cells treated with vitamin C alone were 1.03 and 0.91 for cells treated with 1 mM and
10 mM vitamin C, respectively. Doxorubicin dose is plotted along the x-axis; surviving
fraction is plotted along the y-axis. Both doxorubicin dose and surviving fraction are
shown on a logarithmic scale.

Cell survival decreases with increasing dose of

doxorubicin in all three groups, illustrated by the down-sloping curves.

There is no difference in the survival curves of cultures treated with 0, 1, or
10 mM ascorbic acid, as can be seen from the overlapping error bars in the figure. The
Wilcoxon test was performed and no statistically significant difference was found
between the control group and the cells exposed to 1 mM ascorbic acid (p = 1.0), between
the control group and the cells exposed to 10 mM ascorbic acid (p = 0.75), or between the
cells exposed to 1 mM and 10 mM ascorbic acid (p = 0.75). This data suggests that
L-ascorbic acid has no effect on the sensitivity of EMT6 mouse mammary carcinoma
cells to the antineoplastic agent doxorubicin.
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FIGURE 6. Effects of L-ascorbic acid on the response of exponentially growing
EMT6 cells to doxorubicin.

Points are geometric means ± S.E.M.s of survivals

determined in 3 independent experiments. Key: λ represents control cells;  represents
cells exposed to 1 mM L-ascorbic acid for 4 hours; ▼ represents cells exposed to 10 mM
L-ascorbic acid for 4 hours. All cells were exposed to the indicated dose of doxorubicin
for 2 hours.
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DISCUSSION

The aim of this research was to elucidate any modulatory effect ascorbic acid may
have on the cytotoxic effects of radiation or doxorubicin on EMT6 mouse mammary
carcinoma cells. The findings from the radiation studies reported here demonstrate that
vitamin C decreases the radiosensitivity of EMT6 tumor cells. The dose-modifying
factors for 1 mM and 10 mM ascorbic acid as compared to controls were 1.23 and 1.37,
respectively. This indicates a radioprotective effect of vitamin C. Furthermore, greater
radioprotective effect is seen with the higher concentration of vitamin C. Specifically,
the data show that in order to achieve the same level of cell damage in the presence of
1 mM or 10 mM vitamin C, one would have to administer a dose of radiation 1.23 or 1.37
times that actually given, respectively. No chemomodulatory effects of vitamin C were
observed in the doxorubicin studies.

It is important to view these results in the context of other research that has been
done on vitamin C and its potential role as an adjuvant treatment in cancer therapy. The
clinical question is essentially this: given the well-established antioxidant properties of
vitamin C, does vitamin C reduce the toxicity of radiotherapy or chemotherapy to normal
tissues without compromising their antineoplastic effects? Furthermore, if this question
cannot be definitively answered on the basis of current medical research, what
recommendation about vitamin C supplementation should be made to cancer patients
undergoing conventional treatment?
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Because the results of this thesis support the hypothesis that vitamin C alters the
antitumor effects of radiation but not of doxorubicin, this discussion will focus on the
existing evidence for and debate over whether vitamin C is beneficial to cancer patients
undergoing radiotherapy.

Overall, in vitro and animals studies investigating the

interaction between ascorbic acid and radiotherapy have been contradictory and
inconclusive (24-31). Particularly concerning for its clinical implications is the fact that
some studies not only fail to find a beneficial effect of vitamin C, but rather demonstrate
that vitamin C may actually cause harm by reducing the antineoplastic efficacy of
conventional therapies (24, 37).

Of course, although cell culture and animal data are important in deciphering the
interactions of vitamin C with conventional cancer therapies, a randomized, double-blind,
placebo-controlled clinical trial is necessary to definitively answer the question of
whether vitamin C supplementation has a role to play in cancer treatment. Such a trial
would need to include large numbers of patients to have sufficient power to detect small
but important differences between the vitamin C and control groups. To date, no such
clinical trial has been done. The closest approximation is an historical cohort study
conducted in 2002 by Lesperance et al. (45). In this study, survival and recurrence
outcomes for 90 women with unilateral non-metastatic breast cancer who had been
prescribed mega-doses of vitamin C in addition to other vitamins and minerals while
concurrently undergoing conventional therapy were compared to 180 rigorously-matched
controls. Patients were not excluded from the study based on the type of conventional
treatment received. Sixty-nine percent of study subjects were treated with systemic
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therapy, with or without radiation or surgery.

Sixty-five percent were treated with

radiation, with or without systemic therapy or surgery; the radiation status of 6 percent of
the patients is unknown. Results showed shorter disease-free survival and breast cancerspecific survival for the mega-dose vitamin group compared to controls. Although these
differences were not statistically significant (p = 0.07 for disease-free survival; p = 0.16
for breast cancer-specific survival) they none-the-less reinforce the concern that the use
of high-dose vitamin C during cancer therapy cannot be assumed to be benign.

As always in the quest to find more efficacious and better-tolerated treatments for
cancer, the concept of the therapeutic ratio is both clinically relevant and important. The
therapeutic ratio is defined as the maximum tolerated dose of a drug to the effective dose.
When assessing the clinical benefit of any potential therapy modulator, such as vitamin C,
it is imperative to consider the effect on the response of the tumor as well as the effect on
the response of the dose-limiting normal tissues. Treatments that lead to equal changes in
tumor response and dose-limiting normal tissue response will have a net effect of zero
improvement in outcome. Only those treatments that increase tumor response relative to
the dose-limiting normal tissue response will result in therapeutic gain (22). Following
this logic, in order to demonstrate the value of vitamin C as an adjuvant therapy to
radiation, it is not sufficient to show that vitamin C protects dose-limiting normal tissues
from radiation injury. One must also provide evidence that there is relative protection of
these normal tissues compared to the tumor.

45
The scientific and medical data currently available do not provide sufficient
evidence to support the claim that vitamin C improves the therapeutic ratio of either
radiation or doxorubicin. In fact, results of the research conducted for this thesis suggest
that high-dose ascorbic acid may actually decrease the efficacy of radiotherapy. Given
the high prevalence of complementary and alternative medicine use among cancer
patients, it is extremely important that clinicians address the topic of vitamin
supplementation with their patients who are undergoing standard therapy. In her recent
review article of antioxidants during chemotherapy and radiotherapy, D’Andrea cautions
that if antioxidants compromise the efficacy of cancer treatment by even a few
percentage points, their use could lead to hundreds or thousands of deaths per year (46).
Until proven otherwise, high-dose vitamin C must be considered potentially dangerous
when taken by cancer patients concomitantly with radiation, and patients should be
advised against it.
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